12. Kupelian PA, Potters L, Khuntia D et al. (2004) Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. *Int J Radiat Oncol Biol Phys* 58: 25–33
13. Lawton CA, Desilvio M, Roach M 3rd et al. (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94–13, with emphasis on unexpected hormone/radiation interactions. *Int J Radiat Oncol Biol Phys* 69: 646–655
14. Lawton CA, Winter K, Murray K et al. (2001) Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. *Int J Radiat Oncol Biol Phys* 49: 937–946
15. Mercader M, Bodner BK, Moser MT et al. (2001) T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. *Proc Natl Acad Sci USA* 98: 14565–14570
16. Paulson DF, Lin GH, Hinshaw W et al. (1982) Radical surgery versus radiotherapy for adenocarcinoma of the prostate. *J Urol* 128: 502–504
17. Pilepich MV, Winter K, John MJ et al. (2001) Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. *Int J Radiat Oncol Biol Phys* 50: 1243–1252
18. Pilepich MV, Winter K, Lawton CA et al. (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85–31. *Int J Radiat Oncol Biol Phys* 61: 1285–1290
19. Pollack A, Hanlon AL, Horwitz EM et al. (2004) Prostate cancer radiotherapy dose response: an update of the fox chase experience. *J Urol* 171: 1132–1136
20. Pollack A, Zagars GK, Starkschall G et al. (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. *Int J Radiat Oncol Biol Phys* 53: 1097–1105
21. Roach M 3rd, Desilvio M, Lawton C et al. (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. *J Clin Oncol* 21: 1904–1911
22. Roach M 3rd, Marquez C, Yuo HS et al. (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys* 28: 33–37
23. Robinson JW, Moritz S, Fung T (2002) Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. *Int J Radiat Oncol Biol Phys* 54: 1063–1068
24. Shipley WU, Lu JD, Pilepich MV et al. (2002) Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86–10. *Intern J Rad Oncol Biol Phys* 54: 1302–1310
25. Slater JD, Rossi CJ Jr, Yonemoto LT et al. (2004) Proton therapy for prostate cancer: the initial Loma Linda University experience. *Int J Radiat Oncol Biol Phys* 59: 348–352
26. Spiotto MT, Hancock SL, King CR (2007) Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. *Int J Radiat Oncol Biol Phys* 69: 54–61
27. Tsuji H, Yanagi T, Ishikawa H et al. (2005) Hypofractionated radiotherapy with carbon ion beams for prostate cancer. *Int J Radiat Oncol Biol Phys* 63: 1153–1160
28. Zelefsky MJ, Cowen D, Fuks Z et al. (1999) Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. *Cancer* 85: 2460–2468
29. Zelefsky MJ, Fuks Z, Hunt M et al. (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. *J Urol* 166: 876–881
30. Zietman AL, Prince EA, Nakfoor BM et al. (1997) Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. *Int J Radiat Oncol Biol Phys* 38: 1067–1070
31. Zietman AL, Shipley WU (1993) Randomized trials in loco-regionally confined prostate cancer: past, present, and future. *Semin Radiat Oncol* 3: 10–220

Urologe 2008 · 47:1430
 DOI 10.1007/s00120-008-1889-9
 Online publiziert: 25. Oktober 2008
 © Springer Medizin Verlag 2008

L. Weißbach · C. Schaefer
 Urologische Klinik, EuromedClinic, Fürth

Organ erhaltende Hodentumorchirurgie

Urologe (2008) 47: 809–817

Der Autor macht darauf aufmerksam, dass im oben genannten Beitrag ein Fehler unterlaufen ist.

Im Kapitel „Operative Organerhaltung bei malignen Hodentumoren“ ist die Prozentangabe zur Assoziation einer kontralateralen testikulären intraepithelialen Neoplasie nach Dieckmann et al. [6] falsch. Richtig ist 5,13% (und nicht 9% wie angegeben). Die Autoren bitten den Fehler zu entschuldigen.

Korrespondenzadresse

Prof. Dr. L. Weißbach
 Urologische Klinik, EuromedClinic
 Europa-Allee 1, 90763 Fürth
 weissbach@euromed.de

Die Online-Version des Originalartikels können Sie unter <http://dx.doi.org/10.1007/s00120-008-1711-8> finden.